Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 596 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Raises Key Issues on Cancer Prevention and Care at the WHO Executive Board Meeting Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French MOST POPULAR Concurrent Chemoradiotherapy Followed by Adjuvant Cisplatin-Gemcitabine for the Treatment of Patients... June 15, 2023 Neoadjuvant Pertuzumab/Trastuzumab Demonstrates Long-Term Cardiac Safety in HER2-Positive Breast Cancer May 7, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib July 31, 2025 How Writing Helped Me Cope During Cancer April 27, 2021 Load more HOT NEWS Alex Trebek Has Completed Chemo And Will Be Back For The... FDA Approvals Expand Initial Treatment Options for Multiple Myeloma Talazoparib Plus Enzalutamide Improves rPFS Over Placebo Plus Enzalutamide in First-Line... Can Immunotherapy Succeed in Glioblastoma?
